

# 1           **Multimomics reveals gut dysbiosis contributes to fatty acid** 2           **dysmetabolism in early phase of acute myocardial infarction**

3

## 4           **Authors**

5           Yong Fan<sup>a</sup>, Jiajun Ying<sup>a,b,c</sup>, Ning Huangfu<sup>a,b,c</sup>, Kewan He<sup>a,d</sup>, Teng Hu<sup>a</sup>, Pengpeng Su<sup>e</sup>,  
6           Xintao Hu<sup>a</sup>, Hequn He<sup>f</sup>, Wei Liang<sup>g</sup>, Junsong Liu<sup>b</sup>, Jinsong Cheng<sup>b</sup>, Shiqi Wang<sup>b</sup>, Ruochi  
7           Zhao<sup>b</sup>, Hengyi Mao<sup>b</sup>, Fuwei He<sup>b</sup>, Jia Su<sup>b</sup>, Honglin Zhou<sup>b</sup>, Zhenwei Li<sup>b</sup>, Xiaohong Fei<sup>b</sup>,  
8           Xiafei Sun<sup>b</sup>, Peipei Wang<sup>b</sup>, Minfang Guan<sup>b</sup>, Weiping Du<sup>b</sup>, Shaoyi Lin<sup>b</sup>, Yong Wang<sup>b</sup>,  
9           Fangkun Yang<sup>a</sup>, Renyuan Fang<sup>b</sup>, Ziqing Kong<sup>h</sup>, Xiaomin Chen<sup>a,b,c,\*</sup>, Hanbin Cui<sup>a,b,c,\*</sup>

10          Yong Fan and Jiajun Ying contributed equally to this work.

11

## 12          **Affiliations**

13          <sup>a</sup> Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang  
14          Province, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China.

15          <sup>b</sup> Cardiology Center, The First Affiliated Hospital of Ningbo University, Ningbo 315000,  
16          China.

17          <sup>c</sup> Ningbo Clinical Research Center for Cardiovascular Disease, Ningbo 315000, China.

18          <sup>d</sup> Present address: Department of Ultrasound, The Affiliated Hospital of Ningbo  
19          University, LiHuiLi Hospital, Ningbo 315040, China.

20          <sup>e</sup> Wenzhou Medical University, Wenzhou 325035, China.

21          <sup>f</sup> Department of Emergency, The First Affiliated Hospital of Ningbo University, Ningbo  
22          315000, China.

23          <sup>g</sup> Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo  
24          315000, China.

25          <sup>h</sup> Calibra Lab in DI'AN Diagnostics, Key Laboratory of Digital Technology in Medical  
26          Diagnostics of Zhejiang Province, Hangzhou 310030, China.

27

28          \* Corresponding author: X.C. (email: [chxmin@hotmail.com](mailto:chxmin@hotmail.com)) or

29          NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.  
H.C. (email: [hbcui\\_hbuiyy@outlook.com](mailto:hbcui_hbuiyy@outlook.com))

30 **Abstract**

31 **Background:** Acute myocardial infarction (AMI) remains a major cause of death, with  
32 limited understanding of its early risk stratification. While late-stage AMI has  
33 recognized associations with gut microbiome disturbances, the connection to eAMI is  
34 less explored.

35 **Methods:** Using metabolomics and metagenomics, we analyzed 56 samples,  
36 comprising 30 eAMI patients (within 12 hours of onset) and 26 age- and gender-  
37 matched healthy controls, to discern the influence of gut microbes and their  
38 metabolites.

39 **Results:** We found the eAMI plasma is dominated by increased long-chain fatty acids  
40 (LCFAs), 14 of which provide differentiating power of eAMI patients from HCs.  
41 Multiomics analysis reveals up to 70% of the variance in LCFAs of eAMI patients can  
42 be explained by altered gut microbiome. Higher-resolution profiling of gut bacterial  
43 species demonstrated that bacterial structural variations are mechanistically linked to  
44 LCFAs dysregulation. By *in silico* molecular docking and *in vitro* thrombogenic assay in  
45 isolated human platelets, we highlighted that eAMI-associated LCFAs contribute to  
46 platelet aggregation, a driving factor for AMI initiation.

47 **Conclusions:** LCFAs hold significant potential as early biomarkers of AMI and gut  
48 microbiome contributes to altered LCFAs in eAMI. Further studies are imperative to  
49 expand upon these observations to better leverage LCFAs as a potential biomarker  
50 for eAMI and as a therapeutic target for inhibition of platelet aggregation in eAMI.

51

52

## 53 Introduction

54 Acute myocardial infarction (AMI), the most lethal type in coronary artery disease  
55 (CAD) and primary cause leading to human mortality and morbidity(1-3), is mainly  
56 resulted from the rupture or erosion of atherosclerotic plaque, accompanied by the  
57 formation of an occlusive or sub-occlusive thrombus in one or more coronary artery  
58 branches(4,5). Accordingly, AMI is divided into two subtypes, ST-segment elevation  
59 myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction  
60 (NSTEMI). It has been showed that systemic or local inflammation, imbalance in  
61 adaptive immune pathways can modulate atherosclerotic plaque activity and  
62 contribute to coronary dysfunction and myocardial ischemic necrosis(5-7). However,  
63 the exact underlying mechanism responsible for the progression of coronary artery  
64 disease and occurrence of adverse event remains unclear.

65 A rising body of epidemiological study suggests that gut microbiota have a pivotal  
66 role in low-grade inflammatory metabolic diseases such as obesity(8) and  
67 diabetes(9), which are considered risk factor for atherosclerotic development.  
68 Thereafter, pathological evidence indicates that bacteria from the gut or the oral  
69 cavity might translocate to and reside in atherosclerotic plaques and could affect the  
70 development of atherosclerotic cardiovascular disease (ASCVD)(10,11). Improved  
71 sequencing technology and bioinformatics analyses have provided the several  
72 significant associations between the microbiota taxa and ASCVD(12,13).

73 On how gut microbiota promote to the development of ASCVD, we have summarized  
74 recent advances in the atherosclerosis-linked alterations in gut microbiome,  
75 highlighting the microbiota-related circulating metabolites that accelerate the  
76 development of ASCVD(14). Microbiota-synthesized metabolites such as  
77 trimethylamine N-oxide, secondary bile acids, short-chain fatty acids,  
78 lipopolysaccharides and phenylacetylglutamine have been recognized as the  
79 important contributor to atherosclerotic consequences. Nevertheless, whether gut  
80 microbiota participate in the initiation of AMI, some observational study reported  
81 the statistical correlation between gut bacteria profiling and AMI clinical phenotype.  
82 However, results are inconsistent across previous findings(15,16).

83 So far, the reported investigations on the associations between intestinal microbes  
84 and AMI recruited mostly patients in the late or stable stage of AMI, sparse report on  
85 very early phase of disease has been shown. Whether gut microbes contribute to the  
86 early stage of AMI (eAMI) lesion through its derived metabolites remains unknown.  
87 Here, we recruited a cohort of 30 patients with eAMI within 12 hours and 26 normal  
88 controls, for whom we performed metagenomic sequencing of the gut microbiome  
89 and plasma metabolomics. We found that long-chain fatty acids (LCFAs) dominate  
90 the metabolome perturbations in eAMI plasma, and the gut microbiome at species  
91 level explains up to 70% of the variance in LCFAs composition in eAMI patients. We  
92 also found that eAMI-associated LCFAs may possess potent thrombogenic  
93 functionality by molecular docking and platelet aggregation assay, which furtherly  
94 supports the rational for causal relationship between altered gut microbiota and the  
95 initiation of AMI.

96

97

## 98 **Materials and methods**

### 99 **Study design and cohort description**

100 This study enrolled 30 AMI patients and 26 normal controls who were hospitalized in  
101 the First Affiliated Hospital of Ningbo University from February 2021 to November  
102 2021. Participants were in strictly conformity with the inclusion and exclusion criteria  
103 (**Figure S1**). The diagnosis of AMI is based on the guidelines of the American Heart  
104 Association (ACC) in 2021(17).

105 Inclusion criteria were diagnoses of AMI defined as follows: cardiac troponin (cTn)  
106 I/T > the upper limit of the 99% normal reference value and have any one or more of  
107 the following: significant chest pain of myocardial ischemia; changes in newly  
108 diagnosed ischemic electrocardiogram (ST-T changes or left bundle branch block or  
109 pathological Q wave); imaging evidence suggested new loss of myocardial activity or  
110 regional wall motion abnormalities; abnormal coronary angiography.

111 Exclusion criteria were: history of digestive diseases; severe hepatic and renal  
112 dysfunction; history of autoimmune diseases, malignant hematological diseases and  
113 tumor; infection within one month of the study or the use of antibiotic or probiotic.  
114 Normal controls were hospitalized for health examination at the same period.

115 The study protocol was approved by the Ethics Committee of The First Affiliated  
116 Hospital of Ningbo University (No. 2021-R018-YJ01). The study was performed in  
117 accordance with the principles of the Declaration of Helsinki. All participants  
118 provided written, informed consent for participation in the study.

### 119 **Sample collection and biochemical analysis**

120 Peripheral venous blood was drawn immediately after the patients arrived at the  
121 emergency department, or first moments after hospitalization for normal control  
122 individuals. Blood samples were centrifuged immediately at 4 °C, 4000 rpm for 10  
123 minutes, and the supernatant (plasma) was stored at -80 °C for further analysis. The  
124 first morning fresh fecal (each 400-600 mg) and urine samples were collected from all

125 the participants under the hospital diet, then placed into sterile cryotube and frozen  
126 at -80°C refrigerator before further use.

127 Whole blood samples for biochemical measurements were collected after at least 10-  
128 hour fasting period. The measurements of fasting glucose, lactate dehydrogenase,  
129 creatine kinase, c-reactive protein, serum alanine aminotransferase, aspartate  
130 aminotransferase, glutathione S-transferase, creatinine, glycated serum protein, high-  
131 density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoproteins,  
132 lipoprotein, and serum amyloid A were performed by an autoanalyzer (AU5800,  
133 Beckmancoulter). HbA1C was measured by an automated clinical analyzer (H100plus,  
134 Lifotronic). Plasma brain natriuretic peptide level was measured by a full-automatic  
135 chemiluminescence immunoassay analyzer (Cobas e602, Roche). Plasma troponin  
136 was measured using an autoanalyzer (DXI800, Beckmancoulter). Urine samples were  
137 analyzed by urine sediment analyzer (UF-5000, Sysmex).

### 138 **Pseudo-targeted metabolomics profiling and preprocessing**

139 Metabolomic profiling was performed utilizing the CalOmics metabolomics platform  
140 at Calibra Lab, affiliated with DIAN Diagnostics. The analytical instrumentation  
141 comprised an ACQUITY 2D UPLC system (Waters, Milford, MA, USA) coupled with a Q  
142 Exactive (QE) hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher  
143 Scientific, San Jose, USA). Metabolites were analyzed, based on the chemical  
144 properties of the serum metabolites, utilizing both polar ionic and lipid modes.

145 Sample preparation involved the extraction of metabolites using a methanol solvent  
146 at a 1:4 ratio. Following extraction, mixtures were shaken for three minutes and  
147 subsequently subjected to centrifugation at 4000 × g for 10 minutes at 20°C to  
148 precipitate proteins. The resulting 100 µL aliquots of supernatant were transferred  
149 onto sample plates, dried under a stream of nitrogen, and reconstituted in  
150 appropriate solvents for injection into the UPLC-MS/MS system.

151 The QE mass spectrometer settings included a mass resolution of 35,000 and a scan  
152 range from 70 to 1000 m/z. For the first UPLC-MS/MS method, the instrument

153 operated in positive electrospray ionization (ESI) mode using a C18 reverse-phase  
154 UPLC column (UPLC BEH C18, 2.1x100 mm, 1.7  $\mu$ m; Waters). The mobile phases  
155 consisted of water (A) and methanol (B) with 6.5 mM ammonium bicarbonate at pH  
156 8 for gradient elution. The third method similarly employed the C18 reverse-phase  
157 column in ESI positive mode, but used a mobile phase of water (A) and a mixture of  
158 methanol, acetonitrile, and water (B) containing 0.05% perfluoropentanoic acid  
159 (PFPA) and 0.01% formic acid (FA). In the fourth method, the system was operated in  
160 negative ESI mode with a hydrophilic interaction liquid chromatography (HILIC)  
161 column (UPLC BEH Amide, 2.1x150 mm, 1.7  $\mu$ m; Waters), and the mobile phases  
162 were water (A) and acetonitrile (B) containing 10 mM ammonium formate.

163 Following the preprocessing of raw data and rigorous data quality control  
164 assessments, ion peaks were extracted employing proprietary in-house information  
165 technology hardware and software systems. Metabolites were subsequently  
166 identified through querying a bespoke library, which was compiled using pure  
167 standards sourced from commercial providers or other available channels. The  
168 identification protocol for metabolites within the samples was stringent, requiring a  
169 precise match across three specific criteria when compared to the library entries: a  
170 narrow retention index window, mass accuracy within a 10 ppm deviation, and  
171 tandem mass spectrometry (MS/MS) spectra that exhibit high scores in both forward  
172 and reverse searches. Quantification of each metabolite was achieved by calculating  
173 the peak area using the area-under-the-curve (AUC) method. This approach ensures  
174 accurate measurement of metabolite concentrations within the samples.

175 Before statistical analysis, raw peak areas were normalized to adjust for system  
176 fluctuation among different run days. The normalized peak areas were then log-  
177 transformed ( $\log_2$ ) to reduce data distribution skewness and be in approximate  
178 normal distribution (Gaussian distribution). Missing values in peak area matrix were  
179 imputed by using the minimal detection value of a metabolite among all tested  
180 samples.

## 181 **DNA extraction and library construction of fecal samples**

182 Deoxyribonucleic acid (DNA) was extracted from fecal samples utilizing the  
183 cetyltrimethylammonium bromide (CTAB) method. Control samples included unused  
184 swabs which were processed identically through the DNA extraction protocol to  
185 ensure absence of DNA amplification products. The resultant DNA was eluted in 50  $\mu$ l  
186 of elution buffer, following a modified protocol provided by QIAGEN, and preserved  
187 at -80°C for subsequent analyses.

188 For polymerase chain reaction (PCR) analysis, the samples were processed at LC-BIO  
189 Technologies Co., Hangzhou, China. The construction of the DNA library was  
190 accomplished using the TruSeq Nano DNA LT Library Preparation Kit (FC-121-4001).  
191 Fragmentation of the DNA was performed using dsDNA Fragmentase (NEB, M0348S)  
192 at 37°C for 30 minutes. This step produced blunt-ended DNA fragments via a  
193 combination of fill-in reactions and exonuclease activity. Size selection was then  
194 conducted using the sample purification beads provided in the kit.

195 To prepare the DNA fragments for adapter ligation, an adenine (A) base was added to  
196 the blunt ends of each strand. Each adapter, designed with a thymine (T) base  
197 overhang, facilitates the ligation to the A-tailed DNA fragments. These adapters are  
198 crucial as they contain necessary sites for the hybridization of sequencing primers,  
199 enabling single, paired-end, and indexed sequencing reads.

200 Ligation involved either single or dual index adapters, and the products were  
201 subsequently amplified via PCR. The amplification parameters included an initial  
202 denaturation at 95°C for 3 minutes, followed by 8 cycles of denaturation at 98°C for  
203 15 seconds, annealing at 60°C for 15 seconds, extension at 72°C for 30 seconds, and a  
204 final extension at 72°C for 5 minutes. This process prepares the library for high-  
205 throughput sequencing analyses.

## 206 **Metagenomic sequencing data processing**

207 Raw sequencing data were processed to generate clean reads suitable for  
208 downstream analyses. Initially, sequencing adapters were excised from the reads  
209 using Cutadapt (version 1.9). Subsequently, low-quality reads were trimmed using  
210 fqtrim (version 0.94), which employs a sliding-window algorithm. Reads were then



211 aligned to the host genome using Bowtie2 (version 2.2.0) to eliminate host-derived  
212 sequences. Following the quality filtering, the remaining reads were assembled de  
213 novo using IDBA-UD (version 1.1.1) to construct individual metagenomes for each  
214 sample. Predictions of coding regions (CDS) within the metagenomic contigs were  
215 performed by MetaGeneMark (version 3.26). The CDS sequences across all samples  
216 were clustered using CD-HIT (version 4.6.1) to generate a set of unigenes. Unigene  
217 abundance in each sample was estimated using transcripts per million (TPM) based  
218 on read alignment performed again with Bowtie2 (version 2.2.0). Taxonomic  
219 classification of the unigenes was achieved by aligning them to the NCBI non-  
220 redundant (NR) database using DIAMOND (version 0.9.14). The taxonomic  
221 annotations and abundance profiles of these unigenes were utilized to conduct  
222 differential analysis at both taxonomic and gene-specific levels. Enterotypes profiling  
223 was performed using pipeline as previously demonstrated (18). Phage-inclusive  
224 metagenomics profiling was conducted with Phanta.

### 225 **Profiling of bacterial structural variations**

226 Prior to the structural variations (SVs) classification, the iterative coverage-based  
227 read assignment pipeline was used to precisely reassign the ambiguous reads to the  
228 most likely reference(19,20). The reference genomes given in the proGenomes  
229 database (<http://progenomes1.embl.de/>) were concatenated, separated into  
230 genomic 1-kbp bins, and used for the detection of highly variable genomic variations.  
231 The SGV-Finder pipeline(19) was used to identify SVs that fall into one of three  
232 categories: (1) variable SVs, or vSVs, (2) deletion SVs, or dSVs; the presence or  
233 absence of a specific genomic segment was maintained; or (3) deletion SVs, or dSVs,  
234 with deletion percentages of >75% (this genomic segment was excluded from the  
235 analysis). All bacterial species with SV calling were found in at least 10% of all  
236 samples and were used in the analysis that followed.

### 237 **Molecular docking simulation**

238 The crystal structures of several human receptors were obtained from the RCSB  
239 Protein Data Bank (<https://www.rcsb.org/>). These include the free fatty acid receptor

240 1 (GPR40, PDB ID: 5TZY), the thromboxane A2 receptor (TXA2, PDB ID: 6IIV), and the  
241 P2Y purinoceptors 1 and 12 (PDB IDs: 4XNW and 7PP1, respectively). Subsequent to  
242 download, water molecules and co-crystallized ligands were removed from the .pdb  
243 files to prepare the proteins for molecular docking studies. For the docking  
244 simulations, the receptor structures were prepared by adding polar hydrogen atoms  
245 and computing partial charges using the Kollman and Gasteiger methods. These  
246 modifications were performed using AutoDock Tools (version 1.5.638). The prepared  
247 structures of both ligands and receptors were then saved in .pdbqt format,  
248 facilitating their use in subsequent molecular docking procedures. The molecular  
249 docking studies were performed using the open-source software AutoDock Vina  
250 (version 1.1.2) (21) investigate the interactions between AMI-associated long-chain  
251 fatty acids (LCFAs) and selected receptors involved in platelet aggregation.  
252 Adjustments to the grid box allowed the AutoDock algorithm to predict ligand  
253 conformations within the receptor binding sites and evaluate them using scoring  
254 functions (22), with the grid spacing set at 1 Å. The three-dimensional interactions  
255 between the selected receptors and long-chain fatty acids (LCFAs) were analyzed and  
256 visualized using the PyMOL Molecular Graphics System (version 2.5.0), an open-  
257 source platform. Subsequently, AutoDock version 4.2 was employed to predict the  
258 binding affinities between various ligands and the selected receptors, providing  
259 quantitative insights into the potential binding interactions (23).

## 260 **Thrombogenic effect of LCFAs on isolated human platelets**

261 Fresh platelets were obtained from normal human volunteers without any  
262 antiplatelet or anticoagulant drugs being used within 2 weeks. Whole blood was  
263 collected from the peripheral vein of healthy volunteers into 0.1 vol of ACD buffer (75  
264 mM sodium citrate, 39 mM citric acid, and 135 mM dextrose, pH 6.5). Diluted whole  
265 blood was centrifuged at 1500g for 20 minutes at 25 °C, and platelet-rich plasma  
266 (PRP) was collected into a fresh tube. Then we diluted PRP in ACD buffer, and  
267 centrifuged it at 800g for 10 minutes at 25°C. The platelet pellet was then  
268 resuspended in Tyrode's buffer (137 mM NaCl, 2 mM KCl, 0.34 mM Na<sub>2</sub>HPO<sub>4</sub>, 12 mM

269 NaHCO<sub>3</sub>, 1 mM MgCl<sub>2</sub>, 5.5 mM glucose, 5 mM HEPES, and 0.35% BSA, pH 6.5) at 10<sup>9</sup>  
270 platelets/mL, and kept at 23 °C for up to 4 h before use.

271 Incubations of washed human platelets with fatty acids were done either in pH 6.5  
272 phosphate buffer or in "pH 7.4 Tris buffer" (15.4 mM Tris-Cl, pH 7.4; 140 mM NaCl,  
273 5.6 mM glucose(24)). Candidate LCFAs to be tested were chosen according to the  
274 results shown in **Figure 2a**. Then individual LCFA was diluted to specific concentration  
275 (1 mM, 2.5mM, 5mM and 10mM) by bovine serum albumin solution (BSA),  
276 respectively. Platelet aggregations were measured using a lumi-aggregometer  
277 (AG800, Shandong, China) at 37 °C under stirring at 1200 rpm.

## 278 **Statistical analysis**

279 In this study, no data were excluded before the statistical analysis. As the study is  
280 observational, no allocation or randomization was used. This study includes all  
281 available samples (n = 56) of patients with AMI and healthy individuals. Although  
282 sample sizes were not predetermined using statistical methods, our sample sizes are  
283 comparable to those published earlier(25,26). The distribution of samples among  
284 metagenomics and metabolomics batches was random. During the data collecting  
285 phases of the metagenomic, biochemical, and metabolomics, researchers were  
286 blinded to the group allocation.

287 All statistical analyses were performed with R (version 4.2.3). Significantly differed  
288 metabolites or taxa between AMI and control groups were found by parametric  
289 (student's *t*-test) or non-parametric (Wilcox's rank test) statistical methods.  
290 Multivariate analysis approaches including principal component analysis (PCA),  
291 principal coordinate analysis (PCoA), and random forest (RF) were also conducted.  
292 Permutational multivariate ANOVA (PERMANOVA) was performed to determine the  
293 differences in structures of global microbiome and LCFAs between AMI patients and  
294 controls by using *vegan* (v2.6-4) package. The association analysis between omics  
295 features were performed by spearman correlation using *cor.test* base command.  
296 Least absolute shrinkage and selection operator (LASSO) regression model was built  
297 by using *glmnet* (v4.1-7) package. Unless otherwise stated, all p values were

298 corrected using the Benjamini-Hochberg method and  $P_{adj} < 0.05$  was considered  
299 statistically significant.

300

## 301 **Results**

### 302 **Plasma metabolome and gut microbiome from a deeply phenotyped eAMI cohort**

303 We profiled plasma samples collected from 30 early acute myocardial infarction  
304 (eAMI) patients (within 12 hours in emergency) and 26 age- and gender-matched  
305 healthy controls (HC), using mass spectrometry. For these participants, we also  
306 characterized gut microbiota by performing shotgun metagenomic sequencing of  
307 fecal samples. In addition, as shown in **Table 1**, it is important to note that HC in this  
308 study had no obstructions in any of their coronary arteries, which was validated by  
309 coronary angiography, in addition to having bioclinical characteristics that were  
310 within healthy thresholds. As expected, eAMI patients are distinct from HC with  
311 elevated troponin, pro-BNP, and creatine kinase (p values  $< 1.0e-03$ ) despite  
312 matching for age, sex, BMI and T2D status. Also, eAMI patients display increased  
313 inflammatory markers including C-reactive protein, white blood cells, neutrophils,  
314 and lymphocytes (p values  $< 1.0e-03$ ).

315 A pseudo-targeted metabolomics platform was used to profile 926 identified  
316 metabolites, as well as 26 partially characterized features (**Table S1**). Metabolites  
317 belonged to diverse biochemical classes, including lipids, amino acids, xenobiotics,  
318 nucleotides, and carbohydrates (**Figure S2a**). Most metabolites (877) were measured  
319 in over 50% of the cohort, and 555 metabolites were present in all samples (**Figure**  
320 **S2b**). All the samples were randomly injected and median of RSDs for the internal  
321 standards used in the quality control samples is 2.78%, demonstrating the high  
322 quality of metabolomics data.

323 Bacterial DNA was extracted from fecal samples, sequenced on the Illumina platform,  
324 and a total of 402 Gb 150-bp paired-end reads were generated, with an average of  
325  $47.70 \pm 5.98$  (s.d.) million reads per sample (**Table S2**). For each sample, a majority of

326 high-quality sequencing reads (69.03–97.24%) were *de novo* assembled into long  
327 contigs or scaffolds, which were used for gene prediction, taxonomic classification,  
328 and profiling of structural variations (SVs) in bacterial genomes.

### 329 **LCFAs dominate the metabolome perturbations in eAMI plasma**

330 Principal component analysis of the 952 measured compounds is used in **Figure 1a** to  
331 show the remarkable differences in the global plasma metabolome of eAMI patients  
332 compared to HC subjects and individual contrasted metabolites are shown in **Figure**  
333 **S3**. To characterize the dysregulated metabolic pathways in patients with eAMI, we  
334 performed KEGG pathway enrichment analysis of the differential metabolites and  
335 observed that biosynthesis of unsaturated fatty acids (FA) was the most significantly  
336 disrupted in eAMI patients (**Figure 1b**). Moreover, we found that across the eAMI and  
337 HC groups, the 32 LCFAs species (saturated, monounsaturated, and polyunsaturated)  
338 showed considerable inter-individual heterogeneity (**Figure 1c**). Plasma LCFAs  
339 composition also displayed a significant variation between the two groups  
340 (permutational multivariate analysis of variance (PERMANOVA),  $p < 1.0e-03$ ; **Figure**  
341 **1d**), with 28 upregulated LCFAs between patients with eAMI and HC as demonstrated  
342 in the volcano plot (**Figure 1e**).

343 Thereafter, we divided our cohort into a training group (comprising 70% of the  
344 subjects) and a test set (comprising 30% of the subjects) to identify diagnostic  
345 biomarkers for differentiating HC and patients with eAMI. The training dataset was  
346 utilized to perform feature selection using LCFAs in plasma, and the selected features  
347 were then used to create a random forests classifier (**Figure 2a**). With an area under  
348 the receiver operating characteristic curve (AUC) of 0.927 in the training set, the  
349 random forests model by a biomarker panel of 14 LCFAs (**Figure 2b**) allowed  
350 differentiation between HC and eAMI groups (**Figure 2c**). The created classifier was  
351 subsequently used in testing dataset to estimate independent performance of our  
352 model, which had an AUC of 1 (**Figure 2d**). Overall, these findings reveal the  
353 differences of LCFAs alteration is dominant in metabolome perturbations of patients  
354 with eAMI and demonstrate LCFAs may allow to discover more potent biomarkers,  
355 making the diagnosis of eAMI more accessible.

## 356 Alterations in gut microbiome is associated with the LCFA dysmetabolism in eAMI

357 We next explored the underlying factors that regulate LCFA metabolism by factor  
358 analysis, where we found age, sex, and body mass index could only account for up to  
359 10% of the variance in LCFA proportion (**Figure 3a**). This indicates that a large  
360 proportion of LCFA variation remains unexplained and may be attributed to other  
361 variables, for example, gut microbial factors. Consistent to previous reports(12), we  
362 identified that eAMI gut microbiome is not only distinct from but also more  
363 heterogenous than that of HC subjects (**Figure S4**). Furthermore, we found eAMI gut  
364 microbiome is marked by an enrichment in the Bacteroides2 enterotype ( $P_{\text{Fisher's exact test}} = 2.3\text{e-}02$ )  
365 with a slight depletion in Bacteroides1 enterotype ( $P_{\text{Fisher's exact test}} = 3.1\text{e-}$   
366 01, **Figure 3b**), which always represents a marker suggesting a high risk of metabolic  
367 disorders(27).

368 To furtherly understand if gut microbiome is involved in the regulation of LCFAs  
369 during the onset of eAMI, we performed a least absolute shrinkage and selection  
370 operator (LASSO) regression model to compute the variance in each of the detected  
371 LCFAs that can be explained by gut microbiome. Intriguingly, gut microbiome at  
372 species level explains up to 70% of the variance in LCFAs composition in this cohort  
373 (**Figure 3c**). We next sought to identify the potential bacterial taxa that associate with  
374 the LCFAs by spearman correlation. At genus level, *Mycobacteroides*, *Thermus*, and  
375 *Anaerostipes* are inversely linked to LCFAs (**Figure S5**). As shown in **Figure 3d**, we  
376 found *Streptococcus* species were negatively correlated with omega-3  
377 polyunsaturated FAs including FFA 18:4 (n-3), FFA 18:3 (n-3 or -6), and FFA 22:5 (n-3),  
378 which were considered as cardioprotective compounds. Meanwhile, the  
379 *Streptococcus* species were found to be positively correlated with omega-6  
380 polyunsaturated FAs and saturated LCFAs. Moreover, we discovered that the eAMI  
381 gut virome exhibits a decrease in *Vibrio* phage (**Figure 4a**) but enrichments in  
382 *Streptococcus* phage PH10 and *Streptococcus* phage SM1 (**Figure 4b**), both of which  
383 have known hosts that are *Streptococcus* species. *Streptococcus* bacterial species  
384 predominate in the eAMI gut microbiome (**Figure S4a**), although the mechanism  
385 underpinning this dominance is unclear. Nonetheless, the abundance in temperate  
386 lysogenic *Streptococcus* phages may provide some justification. Additionally, the total

387 number of virulent phages found in the eAMI gut microbiome is higher than in the  
388 healthy controls (Figure 4c). The ratio of virulent to temperate phages is also greater  
389 in the eAMI group compared to the HC group.

### 390 **Gut bacterial structural variants profiling in eAMI**

391 Structural variations (SVs) in bacterial genomes can disrupt gene function, thereby  
392 influencing the interactions between bacteria and their hosts (25). As a result,  
393 significant phenotypic and functional alterations within the gut microbiome of  
394 patients with early acute myocardial infarction (eAMI) may arise from differences in  
395 the presence or levels of SVs among genetically similar bacterial strains. Here, we  
396 profiled SVs in all samples and identified 4,234 deletion SVs and 1,948 variable SVs  
397 across 47 bacterial species (**Figures 5a** and **5b**). For some species, we observed  
398 considerable differences in copy number variation. We identified 87 deletion SVs and  
399 18 variable SVs in *Bacteroides uniformis* across 134 individuals, 78 deletions and 15  
400 variable SVs in *Faecalibacterium prausnitzii* in 124 individuals, and 110 deletion SVs  
401 and 55 variable SVs in *Parabacteroides distasonis* in 121 individuals. For the archaeal  
402 microbiota, we only identified SVs in *Methanobrevibacter smithii* in 13 individuals  
403 (**Figures 5a**). To explore potential differences in bacterial genetics, we further  
404 computed the Canberra distance of bacterial SV profiles between eAMI versus HC  
405 (**Figure 5c**). eAMI and HC samples were significantly different in the beta-diversity of  
406 SV composition ( $P_{\text{Wilcoxon}} = 1.4\text{e-}05$ ) and composition of bacterial genetics in eAMI  
407 individuals has less heterogeneity than that of HC subjects.

### 408 **Bacterial genetics associate to LCFAs dysmetabolism in eAMI**

409 Exploring relationships between gut bacterial SVs and plasma LCFAs, we found that  
410 bacterial SVs were significantly related to LCFAs (**Figure 5d**). As a particularly notable  
411 example, in the association analysis between SVs in the *Alistipes shahii* genome and  
412 plasma LCFAs profile, we found that a 3-kbp deletion (*A. shahii*:575-578) was directly  
413 associated with FFA 22:4 and FFA 14:1 but inversely linked to FFA 16:0, indicating that  
414 this deletion SV may be involved in the regulation of LCFAs metabolism in eAMI  
415 (**Figure 5e**). According to gene analysis, the beginning of this specific genomic region

416 in *A. shahii* encodes a 3-oxoacyl-[acyl-carrier protein] reductase (*FabG*, **Figure 5f**),  
417 which is an enzyme catalyzes the NADPH-dependent reduction of beta-ketoacyl-ACP  
418 substrates to beta-hydroxyacyl-ACP products, the first reductive step in the  
419 elongation cycle of fatty acid biosynthesis. This deletion region is more prevalent in  
420 eAMI group compared to HC gut microbiome (**Figure 5g**). In accordance with the  
421 association analysis, we furtherly found that individuals with *A. shahii* genomes  
422 harboring this deletion have higher plasma FFA 22:4 and FFA 14:1 but lower level of  
423 FFA 16:0, compared to participants without this 3-kbp deletion in *A. shahii* genome  
424 (**Figure 5h**).

#### 425 **Molecular docking and thrombosis in human platelets support the thrombogenic** 426 **effect of eAMI-associated LCFAs**

427 We extended our work to *in silico* molecular docking to investigate the molecular  
428 connections that control thrombosis. Four canonical receptors that are involved in  
429 platelet aggregation—free fatty acid receptor 1 (GPR40), thromboxane A2 receptor  
430 (TXA2), P2Y purinoceptor 1 (P2Y1), and P2Y purinoceptor 12 (P2Y12)—were taken  
431 into account as binding receptors in the molecular docking models in addition to the  
432 28 eAMI-associated LCFAs as binding ligands. As shown in **Figure 6a**, we selected the  
433 first-ranked complex models between the various LCFAs and these four receptors.  
434 Interestingly, the molecular docking models estimated substantial interactions  
435 between eAMI-associated LCFAs and four selected receptors, with binding affinity  
436 ranging from -5.7 to -9.1 kJ/mol (**Figure 5a**). Representative docking results for  
437 bindings between the chosen receptors and omega-3, -6, and -9 polyunsaturated FAs  
438 are displayed in **Figure 6b**.

439 Then, using *in vitro* human platelet anticoagulation assay, we aimed to  
440 experimentally validate the thrombogenic effects of eAMI-associated LCFAs. As  
441 shown in **Figure 6c**, we found omega-6 LCFAs significantly stimulate platelet  
442 aggregation at physiological concentrations (1 mM to 10 mM). As a non-ignorable  
443 example, FFA 19:1 (n-9), as a non-omega-6 LCFA, also causes strong thrombosis in  
444 human platelet (**Figure 6d**), while the mechanistic understanding behind this finding  
445 remains unknown. Our results imply suggest that eAMI-associated LCFAs may



446 possess potent thrombogenic functionality, making it fair to assume that they play a  
447 significant role in host cardiometabolic health.

## 448 **Discussion**

449 The factors triggering the onset of AMI and the precise indicators of eAMI remain  
450 unclear. However, the application of plasma metabolomics provides valuable insights  
451 into the search for accurate diagnostic markers for complex conditions such as AMI.  
452 Additionally, comprehensive multi-omics profiling plays a crucial role in unraveling  
453 the underlying mechanisms responsible for AMI. Together, these approaches shed  
454 light on both diagnostic advancements and a deeper dissection disentangling the  
455 complexity of eAMI.

456 By plasma metabolomics profiling, we found that in patients with eAMI, there was a  
457 remarkable increase in 28 LCFAs dominating the altered eAMI metabolome. These  
458 LCFAs encompassed a variety of saturated, monounsaturated, and polyunsaturated  
459 types. When investigating the etiology of LCFA dysmetabolism in eAMI, we initially  
460 examined its correlation with conventional AMI risk factors including age, sex, body  
461 mass index, and potentially diabetes. However, these factors alone could only explain  
462 a maximum of 10% of the variation observed in LCFA proportions. This raises the  
463 question of what accounts for the remaining 90% of LCFA variation. To this end, we  
464 turned our attention to profiling the gut microbiota, as it is widely recognized for its  
465 potential role in regulating the metabolome. The LASSO regression model allows us  
466 to examine various factors influencing LCFA composition and reveals gut microbiome  
467 at the species level accounted for up to 70% of the observed variance in the  
468 composition of LCFAs. This finding suggests a significant association between the gut  
469 microbiome and the alterations in LCFA levels.

470 To gain mechanistic insights behind the gut microbiome-LCFA interactions, we  
471 associated bacterial SVs with LCFAs and observed significant relations. Of specific  
472 interest is a 3-kbp deletion (*A. shahii*: 575-578) representing *FabG* gene, a key  
473 enzyme in reduction step of elongation cycle in fatty acid biosynthesis, which is more  
474 prevalent in eAMI gut microbiome, resulting in a relatively higher plasma FFA 22:4

475 and FFA 14:1 in eAMI patients. Others have already reported the increase of  
476 intracolonic saturated LCFAs positively associated with elevated abundances of  
477 *Prevotella*, *Lactobacillus*, and *Alistipes*(28). Additionally, the presence of *A. shahii* was  
478 also shown to strengthen the positive associations of red meat intake with  
479 trimethylamine N-oxide (TMAO) concentrations levels(29), while increased TMAO  
480 levels enhances platelet hyperreactivity and thrombosis risk(30), and is associated  
481 with an increased risk of incident major adverse cardiovascular events(31). These  
482 findings support that in addition to short-chain fatty acids – which are known gut  
483 microbial products – disturbances in the gut microbiota also contribute significantly  
484 to the variation in plasma LCFAs during eAMI.

485 Indeed, the question arises whether the elevated levels of LCFA in eAMI are merely a  
486 marker or if they hold pathophysiological significance. Considering that platelet  
487 activation is a distinct pathophysiological characteristic of eAMI, we sought to  
488 explore the impact of eAMI-associated LCFA on circulating platelet activation. As  
489 expected, we found a majority of omega-6 LCFAs rather than omega-3 LCFAs dose-  
490 dependently stimulate platelet aggregation. A role for omega-3 polyunsaturated fatty  
491 acids (PUFA) supplementation to achieve cardioprotective effects has also been  
492 shown by attenuating platelet function(32), aligning with our findings. To date, there  
493 is limited conclusive evidence regarding the effect of LCFAs on platelet activation,  
494 except for arachidonic acid (FFA 20:4 (n-6)), a well-known LCFA that activates  
495 platelets. However, our study has yielded intriguing results. We have discovered that  
496 both FFA 19:1 (n-9) (also known as 10-nonadecenoic acid, HMDB0013622) and FFA  
497 22:4 (n-6) (Adrenic acid, HMDB0002226) can significantly induce human platelet  
498 aggregation to a similar degree as arachidonic acid (FFA 20:4 (n-6), see **Figure S6**).  
499 Notably, FFA 22:4 (n-6) can be synthesized from arachidonic acid (FFA 20:4 (n-6)),  
500 which, in turn, can be elongated from FFA 18:2 (n-6), also known as linoleic acid.  
501 These conversions and interactions among omega-6 PUFAs provide a potential  
502 mechanism for their role in activating platelets.

503 Consistent with previous reports(33), the outcome of our *in vitro* experiments  
504 supports many eAMI-associated LCFAs, especially omega-6 PUFAs can promote  
505 platelet aggregation even in normal physiological concentration (1-5 mM). However,

506 lots of epidemiological investigation has found higher intakes of omega-6 PUFA  
507 appear to be safe and may be even more beneficial, hence the AHA supports an  
508 omega-6 PUFA intake of at least 5% to 10% of energy for dietary recommendations of  
509 coronary heart disease(34). In another prospective analyses, higher *in vivo* circulating  
510 and tissue levels of LA and possibly AA were associated with lower risk of major  
511 cardiovascular events(35). Intriguingly, omega-6 PUFA, dihomo- $\gamma$ -linolenic acid (FA  
512 20:3 (n-6)) has been shown to play a role in inhibiting platelet aggregation *ex vivo*, via  
513 COX-1–derived prostanoid metabolites(36). Therefore, it still has the overwhelming  
514 controversial data on potential effects of omega-6 PUFAs on platelet function.

515 While our study offered valuable multi-omics insights into a cohort of patients with  
516 eAMI, uncovering the association between gut dysbiosis and plasma metabolomic  
517 perturbations characterized by the notable enrichment of LCFAs, it is important to  
518 acknowledge certain limitations in our present study. Firstly, we propose that  
519 intestinal microbial disturbances are significantly associated with fatty acid  
520 dysmetabolism based on cross-sectional correlation analysis. However, the causal  
521 relationship between gut microbiota dysbiosis and altered FA metabolism remains  
522 unclear and requires confirmation in prospective cohorts. Secondly, while platelet  
523 activation is a characteristic feature of eAMI, the specific *in vivo* role of LCFAs is still  
524 not well understood, and there is ongoing debate regarding the effect of  $\omega$ -6 LCFAs  
525 on platelet function. Thirdly, we still don't know the direct or indirect effect of gut  
526 microbiota dysbiosis on platelet activation, as well the underlying mechanism  
527 responsible for it, despite there is report on TMAO(30) and  
528 phenylacetylglutamine(37) contributing to platelet hyperreactivity and enhanced  
529 thrombosis potential. Fourthly, although all participants followed a standardized in-  
530 hospital diet and stool samples were collected shortly after hospitalization, the  
531 potential influence of pre-hospital diet on intestinal microbiome and plasma  
532 metabolome profiling, as well as their interaction, cannot be completely ruled out.  
533 Finally, due to the limitations of sample size and the specific population background  
534 included in this study, the conclusions drawn from our findings should be furtherly  
535 validated through large-scale, prospective studies involving diverse regional  
536 populations.

## 537 **Data availability**

538 The metadata are available under restricted access due to participant consent and  
539 privacy regulations of this cohort, access can be obtained by request to the  
540 corresponding author. Access to the metagenomics and metabolomics data may be  
541 granted for statistical and scientific research with approval from the corresponding  
542 author (Hanbin Cui: [hbcui\\_nbdyyy@outlook.com](mailto:hbcui_nbdyyy@outlook.com)).

## 543 **Code availability**

544 Scripts associated with the data analysis and visualization are available at  
545 [https://github.com/fjw536/AMI\\_gut\\_microbiome](https://github.com/fjw536/AMI_gut_microbiome).

## 546 **Acknowledgements**

547 We thank the study participants and nurses for their contributions to the project. We  
548 gratefully acknowledge colleagues at Lianchuan biotechnology for Metagenomics  
549 sequencing analysis of gut microbiota, and DI'AN Diagnostics, Key Laboratory of  
550 Digital Technology in Medical Diagnostics of Zhejiang Province for plasma  
551 metabolomics profiling, data analysis and discussions.

## 552 **Author contributions**

553 Y.F., J.Y. and H.C. conceived and designed the study. J.Y., F.H., K.H., T.H., H.M., P.S. X.H.,  
554 H.M., Z.L., R.Z., J.L., J.C., S.W., X.S., H.H., P.W., M.G., J.S., W.D., Y.W., H.Z., S.L., X.F.,  
555 W.L., R.F., F.H. and X.C. were involved in the acquisition of samples and data. Y.F. and  
556 Z.K. analyzed and interpreted the data. Y.F. and J.Y. drafted the work and H.C.  
557 substantively revised it. All authors contributed to the article and approved the  
558 submitted version.

## 559 **Competing interests**

560 All authors declare no competing interests in this study.

## 561 **Funding**

562 This research was supported by the Key research and development project of  
563 Zhejiang Province, China (no. 2021C03096), Major Project of Science and Technology  
564 Innovation 2025 in Ningbo, China (no. 2021Z134) and Ningbo Clinical Research  
565 Center for Cardiovascular Disease, Ningbo, China (no. 2022L001).

566

## 567 Reference

- 568 1. DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life years  
569 (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries,  
570 1990-2013: quantifying the epidemiological transition. *Lancet* 2015;386:2145-91.
- 571 2. Faxen J, Jernberg T, Hollenberg J, Gadler F, Herlitz J, Szummer K. Incidence and Predictors of  
572 Out-of-Hospital Cardiac Arrest Within 90 Days After Myocardial Infarction. *J Am Coll Cardiol*  
573 2020;76:2926-2936.
- 574 3. Gong W, Yan Y, Wang X et al. Risk Factors for In-Hospital Cardiac Arrest in Patients With ST-  
575 Segment Elevation Myocardial Infarction. *J Am Coll Cardiol* 2022;80:1788-1798.
- 576 4. Anderson JL, Morrow DA. Acute Myocardial Infarction. *The New England journal of medicine*  
577 2017;376:2053-2064.
- 578 5. Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision  
579 Treatment. *Circulation* 2017;136:1155-1166.
- 580 6. Maier W, Altwegg LA, Corti R et al. Inflammatory markers at the site of ruptured plaque in  
581 acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but  
582 decreased C-reactive protein. *Circulation* 2005;111:1355-61.
- 583 7. Granger CB, Kochar A. Understanding and Targeting Inflammation in Acute Myocardial  
584 Infarction: An Elusive Goal. *J Am Coll Cardiol* 2018;72:199-201.
- 585 8. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated  
586 gut microbiome with increased capacity for energy harvest. *Nature* 2006;444:1027-31.
- 587 9. Karlsson FH, Tremaroli V, Nookaew I et al. Gut metagenome in European women with normal,  
588 impaired and diabetic glucose control. *Nature* 2013;498:99-103.
- 589 10. Jonsson AL, Backhed F. Role of gut microbiota in atherosclerosis. *Nature reviews Cardiology*  
590 2017;14:79-87.
- 591 11. Barrington WT, Lusic AJ. Atherosclerosis: Association between the gut microbiome and  
592 atherosclerosis. *Nature reviews Cardiology* 2017;14:699-700.
- 593 12. Jie Z, Xia H, Zhong SL et al. The gut microbiome in atherosclerotic cardiovascular disease.  
594 *Nature communications* 2017;8:845.
- 595 13. Karlsson FH, Fak F, Nookaew I et al. Symptomatic atherosclerosis is associated with an altered  
596 gut metagenome. *Nature communications* 2012;3:1245.
- 597 14. Fan Y, Ying J, Ma H, Cui H. Microbiota-related metabolites fueling the understanding of  
598 ischemic heart disease. *iMeta* 2023;2:e94.
- 599 15. Kelly TN, Bazzano LA, Ajami NJ et al. Gut Microbiome Associates With Lifetime Cardiovascular  
600 Disease Risk Profile Among Bogalusa Heart Study Participants. *Circulation research*  
601 2016;119:956-964.
- 602 16. Liu M, Wang M, Peng T et al. Gut-microbiome-based predictive model for ST-elevation  
603 myocardial infarction in young male patients. *Frontiers in microbiology* 2022;13:1031878.
- 604 17. Gulati M, Levy PD, Mukherjee D et al. 2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR  
605 Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of  
606 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am*  
607 *Coll Cardiol* 2021;78:e187-e285.
- 608 18. Vieira-Silva S, Falony G, Belda E et al. Statin therapy is associated with lower prevalence of gut  
609 microbiota dysbiosis. *Nature* 2020;581:310-315.

- 610 19. Zeevi D, Korem T, Godneva A et al. Structural variation in the gut microbiome associates with  
611 host health. *Nature* 2019;568:43-48.
- 612 20. Wang D, Doestzada M, Chen L et al. Characterization of gut microbial structural variations as  
613 determinants of human bile acid metabolism. *Cell Host Microbe* 2021;29.
- 614 21. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new  
615 scoring function, efficient optimization, and multithreading. *J Comput Chem* 2010;31:455-  
616 461.
- 617 22. Pahonțu E, Proks M, Shova S et al. Synthesis, characterization, molecular docking studies and  
618 in vitro screening of new metal complexes with Schiff base as antimicrobial and  
619 antiproliferative agents. *Appl Organometal Chem* 2019;33:e5185.
- 620 23. Morris GM, Huey R, Lindstrom W et al. AutoDock4 and AutoDockTools4: Automated docking  
621 with selective receptor flexibility. *J Comput Chem* 2009;30:2785-2791.
- 622 24. Neufeld EJ, Wilson DB, Sprecher H, Majerus PW. High affinity esterification of eicosanoid  
623 precursor fatty acids by platelets. *J Clin Invest* 1983;72:214-220.
- 624 25. Fan Y, Støving RK, Berreira Ibraim S et al. The gut microbiota contributes to the pathogenesis  
625 of anorexia nervosa in humans and mice. *Nat Microbiol* 2023;8:787-802.
- 626 26. Kindschuh WF, Baldini F, Liu MC et al. Preterm birth is associated with xenobiotics and  
627 predicted by the vaginal metabolome. *Nat Microbiol* 2023;8:246-259.
- 628 27. Vieira-Silva S, Falony G, Belda E et al. Statin therapy is associated with lower prevalence of gut  
629 microbiota dysbiosis. *Nature* 2020;581:310-315.
- 630 28. Zhao L, Huang Y, Lu L et al. Saturated long-chain fatty acid-producing bacteria contribute to  
631 enhanced colonic motility in rats. *Microbiome* 2018;6:107.
- 632 29. Li J, Li Y, Ivey KL et al. Interplay between diet and gut microbiome, and circulating  
633 concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men. *Gut*  
634 2022;71:724-733.
- 635 30. Zhu W, Gregory JC, Org E et al. Gut Microbial Metabolite TMAO Enhances Platelet  
636 Hyperreactivity and Thrombosis Risk. *Cell* 2016;165:111-124.
- 637 31. Tang WH, Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine  
638 and cardiovascular risk. *The New England journal of medicine* 2013;368:1575-84.
- 639 32. Adili R, Hawley M, Holinstat M. Regulation of platelet function and thrombosis by omega-3  
640 and omega-6 polyunsaturated fatty acids. *Prostaglandins Other Lipid Mediat* 2018;139:10-18.
- 641 33. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. *Progress in lipid research*  
642 2008;47:147-55.
- 643 34. Harris WS, Mozaffarian D, Rimm E et al. Omega-6 fatty acids and risk for cardiovascular  
644 disease: a science advisory from the American Heart Association Nutrition Subcommittee of  
645 the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular  
646 Nursing; and Council on Epidemiology and Prevention. *Circulation* 2009;119:902-7.
- 647 35. Marklund M, Wu JHY, Imamura F et al. Biomarkers of Dietary Omega-6 Fatty Acids and  
648 Incident Cardiovascular Disease and Mortality. *Circulation* 2019;139:2422-2436.
- 649 36. Yeung J, Tourdot BE, Adili R et al. 12(S)-HETrE, a 12-Lipoxygenase Oxylin of Dihomo-gamma-  
650 Linolenic Acid, Inhibits Thrombosis via Galphas Signaling in Platelets. *Arteriosclerosis,*  
651 *thrombosis, and vascular biology* 2016;36:2068-77.
- 652 37. Nemet I, Saha PP, Gupta N et al. A Cardiovascular Disease-Linked Gut Microbial Metabolite  
653 Acts via Adrenergic Receptors. *Cell* 2020;180:862-877 e22.

654

## 655 **Figure legends**

656 **Figure 1 | Long-chain free fatty acids (LCFAs) dominate the metabolome alterations**  
657 **in plasma of early acute myocardial infarction (eAMI) patients compared with**  
658 **healthy control (HC) individuals. (a)** Principal component (PC) analysis demonstrates  
659 the remarkable metabolome alterations in eAMI patients compared with HC  
660 individuals. **(b)** KEGG metabolic pathway enrichment of differential metabolites (FDR-  
661 adjusted  $p < 0.05$ ) between eAMI and healthy controls. Fisher's exact test (one-side)  
662 followed by FDR-adjusted  $p$  value was used and only pathways with FDR-adjusted  $p <$   
663  $0.05$  were shown. **(c)** Proportional structure of 32 detected LCFAs in plasma across all  
664 samples of eAMI and HC individuals. LCFAs are colored by degree of saturation,  
665 saturated LCFAs are colored in yellow, monounsaturated LCFAs are colored in red,  
666 and polyunsaturated LCFAs are colored in blue. **(d)** Principal coordinate analysis  
667 (PCoA) plot of the difference between eAMI and HC groups based on LCFAs  
668 proportion profile. **(e)** Volcano plot of 952 detected metabolites by untargeted  
669 metabolome profiling in eAMI patients and HC individuals. Red dots represent  
670 significantly up-regulated (FDR-adjusted  $p < 0.05$  and Cliff Delta  $> 0.4$ ) metabolites in  
671 eAMI plasma. Blue dots represent notably eAMI-depleted plasma metabolites (FDR-  
672 adjusted  $p < 0.05$  and Cliff Delta  $< 0.4$ ). Grey dots marked the unchanged  
673 metabolites. Significantly altered LCFAs were labeled. The horizontal line represents  
674 FDR cutoff of 0.05 and the vertical lines denote  $|\text{Cliff Delta}| > 0.4$ .

675 **Figure 2 | Machine learning demonstrates long-chain free fatty acids (LCFAs) are**  
676 **potential diagnostic biomarkers for eAMI. (a)** The top 20 most important LCFAs  
677 reducing the variance (mean squared error (%IncMSE)) in classification of eAMI by  
678 random forest model. %IncMSE denotes the increase in mean squared error of  
679 predictions as a result of variable (LCFAs) being permuted. The training model was  
680 constructed by proportional profile of 32 LCFAs in 39 training samples. **(b)**  
681 Distribution of cross-validation error in random forest classification of eAMI patients  
682 as the number of top ranking LCFAs increased. Red dot line marks the optimal  
683 number of LCFAs ( $n = 14$ ) for the classification of eAMI patients. **(c and d)** Receiver  
684 operating characteristic (ROC) curve using the 14 LCFAs optimized by random forest



685 model for the (c) training and (d) test set (right panel,  $n = 17$ ). Vertical heatmap in  
686 each panel denotes specificity for the ROC curve in c and d. AUC, area under the  
687 curve.

688 **Figure 3 | Bacterial alterations characterize eAMI gut microbiome and greatly**  
689 **explain the variance in plasma long-chain free fatty acids (LCFAs).** (a) Density plot  
690 showing sample-wide distribution of (% of explained variances) intrinsic factors  
691 (gender, age, and body mass index (BMI)) associated with the plasma concentrations  
692 of LCFAs. (b) Bar plot demonstrates the variation of 32 LCFAs explained by identified  
693 bacterial taxa at species level using LASSO regression. (c) Stacked bar plot shows the  
694 prevalence of gut enterotypes in eAMI and control groups. (d) Circular heatmap  
695 represents the correlation between LCFAs and gut bacterial species. Only association  
696 groups with FDR-adjusted p value of  $< 0.01$  are colored in this plot.

697 **Figure 4 | Alterations in viral gut microbiota between eAMI and HC groups.** Box  
698 plots showing the relative abundance of increased (a) and decreased (b) viral gut  
699 microbiota at species level in eAMI gut microbiome compared to that of HC group.  
700 Differences in abundance were detected using MaAslin2. (c) Significant variations in  
701 the abundance, abundance ratios, and counts of virulent and temperate phages  
702 between the HC and eAMI groups. Significance was determined by Wilcoxon ranked  
703 sum test. For box plots in all panels, the vertical lines extend 1.5 times the  
704 interquartile range (top and bottom borders of the box) and the median depicted by  
705 the horizontal line inside the box.

706 **Figure 5 | Bacterial structural variations (SVs) links to long-chain free fatty acids**  
707 **profiles in acute myocardial infarction (AMI) patients.** (a) Number of SVs of each  
708 bacterial species in 56 study participants. (b) Pie chart showing the total identified  
709 SVs numbers. (c) Boxplot of Canberra distance between samples within eAMI and  
710 healthy control (HC) groups based on SVs profile, significance is determined by two-  
711 sided Mann-Whitney  $U$ -test. (d) Chord diagram showing significant associations  
712 between LCFAs and bacterial SVs. (e) Heatmap demonstrates the associations  
713 between SVs of *Alistipes shahii* and LCFAs. Only significant correlations with FDR-  
714 adjusted p value of  $< 0.01$  are visualized. ++, FDR-adjusted  $p < 0.01$ , and +++, FDR-

715 adjusted  $p < 0.001$ . **(f)** The deletion rate of the 3-kbp deletion harboring 3-oxoacyl-  
716 [acyl-carrier protein] reductase (FabG) in *Alistipes shahii*. **(g)** Stacking bar plot  
717 represents the prevalence of 3-kbp deletion SV of *Alistipes shahii* in eAMI and HC  
718 groups. **(h)** Relative abundance of LCFAs in individuals with and without the 3-kbp  
719 deletion SV of *Alistipes shahii*. \*\*,  $p < 0.01$ , \*\*\*,  $p < 0.001$  determined by two-sided  
720 Mann-Whitney *U*-test.

721 **Figure 6 | Early acute myocardial infarction (eAMI)-associated long-chain free fatty**  
722 **acids (LCFAs) bind to thrombosis-related receptors and induce thrombosis in**  
723 **human platelets. (a)** Heatmap of binding energies between eAMI-associated LCFAs  
724 and thrombosis-related receptors through molecular docking. Binding affinities are  
725 quantified at kJ/mol. **(b)** The representative AutoDock predicted binding  
726 conformation complex of LCFAs versus thrombosis-related receptors, within which  
727 the receptors are depicted as cartoons and LCFAs as sticks. **(c)** The thrombogenic  
728 impact of eAMI-associated LCFAs on human platelets is depicted in a heatmap.  
729 Platelet aggregation ratios of  $> 10\%$  and  $10\%$  are indicated by blue and grey,  
730 respectively. **(d)** Representative platelet aggregation curves in a time interval of 300  
731 seconds after the treatment of LCFAs at a concentration of 5 mM. Red dashed line  
732 indicates 10% threshold.

733

## 734 **Supplementary Figures**

735 **Figure S1 | Participant flow diagram.** 123 suspected myocardial infarction patients  
736 were contacted, and 30 were eventually enrolled after screening.

737 **Figure S2 | a,** Distribution of measured metabolite super pathways of the 952  
738 metabolites. **b,** Distribution of metabolite prevalence among the 56 samples. Blue  
739 distribution represents prevalence of all analyzed metabolites ( $n = 952$ ). Numbers of  
740 metabolites that are present in more than 50% ( $n = 28$ ) of the samples are indicated  
741 by dashed lines.

742 **Figure S3 | Metabolic alterations in the plasma of eAMI patients.** Heatmap of

743 contrasted metabolites in the plasma of healthy controls (HC) and eAMI patients.

744 **Figure S4 | Alterations in bacterial gut microbiota in eAMI patients.** **a.** Phylogenetic  
745 tree of contrasted bacterial taxa between eAMI and HC bacterial gut microbiota. Taxa  
746 colored in red and blue respectively represents increased and reduced taxa in eAMI  
747 bacterial gut microbiota compared with HC group. **b.** Box plot (line, median; box,  
748 interquartile range (IQR); whiskers, 1.5× IQR) of  $\beta$ -diversity at bacterial species level  
749 (Canberra distance) of eAMI ( $n = 30$ ) and HC ( $n = 26$ ) gut microbiota. Statistical  
750 significances between two groups were determined by Wilcoxon rank-sum test (two-  
751 sided).

752 **Figure S5 | Gut microbiome at genus level associate with long-chain fatty acids**  
753 **(LCFAs) metabolism.** Circular heatmap represents the correlation between LCFAs and  
754 gut bacteria at genus level. Association groups with FDR-adjusted p value of  $< 0.05$   
755 are visualized in this plot.

756 **Figure S6 | Thrombogenic effects of FFA 20:4 (arachidonic acid) in human platelets.**  
757 Platelet aggregation curves in a time interval of 300 seconds after the treatment of  
758 FFA 20:4 at concentrations of 500  $\mu$ M and 1 mM are given in **(a)** and **(b)**, respectively.  
759 Red dashed line indicates 10% threshold.

760

761 **Table 1. Cohort characteristics**

	eAMI, n = 30 <sup>1</sup>	Control, n = 26 <sup>1</sup>	p-value <sup>2</sup>
<b>Sub-classification</b>			
Control	0 (0%)	26 (100%)	
NSTEMI	5 (17%)	0 (0%)	
STEMI	25 (83%)	0 (0%)	
<b>Gender</b>			0.051
Female	3 (10%)	8 (31%)	
Male	27 (90%)	18 (69%)	
<b>Age (ys)</b>	56 (46, 66)	59 (43, 67)	>0.9
<b>BMI (Kg/m<sup>2</sup>)</b>	26.4 (22.9, 28.3)	24.4 (22.0, 26.3)	0.2
<b>Smoking (n)</b>	19 (63%)	4 (15%)	<0.001
<b>Alcohol (n)</b>	10 (33%)	2 (7.7%)	0.020
<b>Hypertention (n)</b>	22 (73%)	9 (35%)	0.004
<b>Diabetes (n)</b>	7 (23%)	4 (15%)	0.5
<b>Other commorbidities (n)</b>	4 (13%)	4 (15%)	>0.9
<b>Antithrombotic (n)</b>	1 (3.3%)	3 (12%)	0.3
<b>Statin (n)</b>	1 (3.3%)	2 (7.7%)	0.6
<b>Antiarrhythmic (n)</b>	2 (6.7%)	2 (7.7%)	>0.9
<b>Antidiabetic (n)</b>	4 (13%)	2 (7.7%)	0.7
<b>Antihypertensive (n)</b>	12 (40%)	8 (31%)	0.5
<b>PPI (n)</b>	1 (3.3%)	1 (3.8%)	>0.9
<b>Culprit vessel (n)</b>			
LM	1 (3.3%)	0 (0%)	>0.9
RCA	16 (53%)	0 (0%)	<0.001
LAD	22 (73%)	0 (0%)	<0.001
LCX	15 (50%)	0 (0%)	<0.001
<b>Emergency troponin (ng/mL)</b>	0 (0, 4)	0 (0, 0)	0.5
<b>Emergency BNP (ng/L)</b>	0.97 (0.13, 2.05)	0.98 (0.98, 0.98)	>0.9
<b>In-hospital troponin (ng/mL)</b>	37 (11, 99)	0 (0, 0)	<0.001
<b>In-hospital Pro-BNP (ng/L)</b>	395 (206, 1,039)	49 (17, 115)	<0.001
<b>LDH (U/L)</b>	0 (0, 473)	133 (133, 133)	0.7
<b>Creatine kinase (U/L)</b>	82 (40, 151)	2 (1, 3)	<0.001
<b>CRP (mg/L)</b>	0.9 (0.0, 3.6)	0.0 (0.0, 0.4)	0.003
<b>WBC (*10<sup>9</sup>/L)</b>	12.4 (10.0, 13.3)	5.9 (4.9, 6.6)	<0.001
<b>Neutrophils (%)</b>	79 (73, 86)	57 (49, 65)	<0.001
<b>Lymphocyte (%)</b>	14 (9, 17)	33 (23, 39)	<0.001
<b>Hemoglobin (g/L)</b>	145 (135, 155)	138 (129, 156)	0.5
<b>RDW (%)</b>	12.50 (12.20, 12.78)	12.50 (12.20, 12.95)	0.7
<b>ALT (U/L)</b>	50 (36, 63)	17 (13, 28)	<0.001
<b>AST (U/L)</b>	252 (90, 358)	22 (18, 24)	<0.001
<b>GST/GLT</b>	3.82 (2.66, 5.49)	1.18 (0.88, 1.38)	<0.001
<b>Creatinine (μmol/L)</b>	73 (66, 88)	68 (55, 80)	0.068
<b>BUN/creatinine</b>	0.075 (0.053, 0.080)	0.070 (0.053, 0.090)	0.7
<b>Uric acid (μmol/L)</b>	361 (301, 513)	325 (252, 384)	0.035
<b>Fasting glucose (mmol/L)</b>	5.9 (5.3, 7.9)	4.9 (4.4, 5.2)	<0.001
<b>HbA1C (%)</b>	5.85 (5.53, 6.35)	5.40 (0.00, 5.77)	0.003
<b>GSP (mmol/L)</b>	1.89 (1.72, 2.19)	1.71 (0.35, 1.86)	0.009
<b>Total cholesterol (mmol/L)</b>	5.32 (4.44, 5.93)	4.24 (3.33, 5.18)	0.002
<b>Triglycerides (mmol/L)</b>	1.44 (0.95, 2.79)	1.19 (0.76, 1.53)	0.042
<b>HDL (mmol/L)</b>	1.01 (0.90, 1.10)	1.00 (0.86, 1.24)	0.9

	eAMI, n = 30 <sup>1</sup>	Control, n = 26 <sup>1</sup>	p-value <sup>2</sup>
<b>LDL</b> (mmol/L)	3.58 (2.92, 4.18)	2.81 (1.98, 3.16)	<0.001
<b>apoB</b> (g/L)	0.98 (0.82, 1.22)	0.59 (0.10, 0.79)	<0.001
<b>apoA1</b> (g/L)	1.02 (0.90, 1.09)	1.02 (0.20, 1.22)	>0.9
<b>LP(a)</b> (mg/L)	14 (9, 25)	7 (0, 24)	0.063
<b>SAA</b> (mg/L)	15 (3, 32)	1 (0, 3)	<0.001
<b>U-occult blood</b> (n)			0.035
no	18 (60%)	20 (77%)	
Yes	12 (40%)	4 (15%)	
<b>U-protein</b> (n)			0.051
no	20 (67%)	21 (81%)	
Yes	10 (33%)	3 (12%)	
<b>U-glucose</b> (n)			0.037
no	23 (77%)	23 (88%)	
Yes	7 (23%)	1 (3.8%)	

762

763 <sup>1</sup>n (%); Median (IQR)

764 <sup>2</sup>Fisher's exact test; Pearson's Chi-squared test; Wilcoxon rank sum test

765 eAMI, early phase of acute myocardial infarction; NSTEMI, non-ST-elevation myocardial

766 infarction; STEMI, ST-elevation myocardial infarction; BMI, body mass index; PPI, proton

767 pump inhibitor; LM, left main; RCA, right coronary artery; LAD, left anterior descending

768 artery; LCX, left circumflex artery; BNP, brain natriuretic peptide; CRP, C-reactive protein;

769 WBC, white blood cell; RDW, red cell distribution width; ALT, alanine transaminase; AST,






770 aspartate transaminase; GST/GLT, glutathione S-transferase; BUN, blood urea nitrogen;





771 HbA1C, hemoglobin A1c; GSP, glycated serum protein; HDL, high-density lipoprotein




772 cholesterol; LDL, low-density lipoprotein cholesterol; apo, apolipoprotein; LP, lipoprotein;

773 SAA, serum amyloid A; U-, uric.




774




















**a****b****c**



**a****b****c****d**